Protection that doesn't wait.

mAbV is developing a new class of prophylactic monoclonal antibodies — immediate, engineered protection for those who can't afford to wait for immunity.

The full picture

Everything you need to know about mAbV

The Problem

A critical window of vulnerability

—Traditional vaccines require 2–6 weeks to generate immunity, leaving patients exposed.
—Immunocompromised, elderly, and newborn patients often fail to respond to active vaccination.
—Complex dosing schedules create compliance barriers in public health programmes.

Our Solution

Instant, engineered protection

✓Pre-formed antibodies deliver instant protection — no lag period.
✓Fc-engineering extends half-life to season-length coverage from a single dose.
✓Effective regardless of the patient's own immune response.

How It Works

Three pillars of the mAbV platform

Precision Targeting

Engineered to bind conserved pathogen regions — minimising escape, maximising neutralisation.

Long-Acting by Design

FcRn recycling pathway engineering extends antibody circulation from weeks to months.

AI-Accelerated Discovery

Oxford University collaboration shortens candidate identification timelines significantly.

Pipeline

Targeting high-burden infectious diseases

mAbV-RSV-01

RSV F-protein · Infant & elderly

Pre-clinical

mAbV-COV-02

SARS-CoV-2 · Immunocompromised

Discovery

mAbV-BROAD-03

Pan-filovirus · Outbreak preparedness

Research

AI Platform

Oxford collab · Cross-pathogen

Active

Research-stage only. No regulatory approval.

Market Opportunity

Category creation, not competition

For Clinicians

Immediate, predictable protection for patients who cannot mount a vaccine response. Single-dose, season-length coverage.

For Biopharma

One platform framework applicable across multiple pathogens. AI-accelerated, asset-light model.

For Investors

Entering the $286B+ mAb market — prophylaxis segment validated by Beyfortus.

About mAbV

Built on scientific rigour

Founded to bridge vaccine biology and monoclonal antibody engineering — applying prophylactic antibodies to infectious diseases where vaccines have historically failed to reach those who need them most.

✓ Oxford University research collaboration
✓ AI-native antibody discovery platform
✓ Singapore / China international positioning with global partnership ambitions

Get in Touch

We'd like to hear from you

Open to discussions with investors, biopharma partners, clinicians, and academic collaborators. We're in early-stage stealth — your interest matters.

contact@mabvbio.com

Design System